Therapeutic Effect of Exendin-4, a Long-Acting Analogue of Glucagon-Like Peptide-1 Receptor Agonist, on Nerve Regeneration after the Crush Nerve Injury

Abstract EN

Glucagon-like peptide-1 (GLP-1) is glucose-dependent insulinotropic hormone secreted from enteroendocrine L cells.

Its long-acting analogue, exendin-4, is equipotent to GLP-1 and is used to treat type 2 diabetes mellitus.

In addition, exendin-4 has effects on the central and peripheral nervous system.

In this study, we administered repeated intraperitoneal (i.p.) injections of exendin-4 to examine whether exendin-4 is able to facilitate the recovery after the crush nerve injury.

Exendin-4 injection was started immediately after crush injury and was repeated every day for subsequent 14 days.

Rats subjected to sciatic nerve crush exhibited marked functional loss, electrophysiological dysfunction, and atrophy of the tibialis anterior muscle (TA).

All these changes, except for the atrophy of TA, were improved significantly by the administration of exendin-4.

Functional, electrophysiological, and morphological parameters indicated significant enhancement of nerve regeneration 4 weeks after nerve crush.

These results suggest that exendin-4 is feasible for clinical application to treat peripheral nerve injury.